Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $2.40 billion. The enterprise value is $2.16 billion.
| Market Cap | 2.40B |
| Enterprise Value | 2.16B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 111.42 million shares outstanding. The number of shares has increased by 36.47% in one year.
| Current Share Class | 111.42M |
| Shares Outstanding | 111.42M |
| Shares Change (YoY) | +36.47% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 7.74% |
| Owned by Institutions (%) | 88.01% |
| Float | 82.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.07 |
| P/TBV Ratio | 10.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.12, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.12 |
| Quick Ratio | 11.88 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -74.73% and return on invested capital (ROIC) is -48.45%.
| Return on Equity (ROE) | -74.73% |
| Return on Assets (ROA) | -44.13% |
| Return on Invested Capital (ROIC) | -48.45% |
| Return on Capital Employed (ROCE) | -66.60% |
| Weighted Average Cost of Capital (WACC) | 3.12% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $46,000 in taxes.
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +169.75% in the last 52 weeks. The beta is -0.20, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | +169.75% |
| 50-Day Moving Average | 18.30 |
| 200-Day Moving Average | 15.25 |
| Relative Strength Index (RSI) | 56.32 |
| Average Volume (20 Days) | 1,978,648 |
Short Selling Information
The latest short interest is 13.40 million, so 12.03% of the outstanding shares have been sold short.
| Short Interest | 13.40M |
| Short Previous Month | 12.27M |
| Short % of Shares Out | 12.03% |
| Short % of Float | 16.23% |
| Short Ratio (days to cover) | 7.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | -90.85M |
| Operating Income | -162.10M |
| Pretax Income | -152.05M |
| Net Income | -152.09M |
| EBITDA | -161.73M |
| EBIT | -162.10M |
| Earnings Per Share (EPS) | -$1.43 |
Balance Sheet
The company has $250.76 million in cash and $5.26 million in debt, with a net cash position of $245.51 million or $2.20 per share.
| Cash & Cash Equivalents | 250.76M |
| Total Debt | 5.26M |
| Net Cash | 245.51M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 239.17M |
| Book Value Per Share | 2.15 |
| Working Capital | 235.19M |
Cash Flow
In the last 12 months, operating cash flow was -$126.58 million and capital expenditures -$140,000, giving a free cash flow of -$126.72 million.
| Operating Cash Flow | -126.58M |
| Capital Expenditures | -140,000 |
| Depreciation & Amortization | 369,000 |
| Net Borrowing | 190.74M |
| Free Cash Flow | -126.72M |
| FCF Per Share | -$1.14 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.47% |
| Shareholder Yield | -36.47% |
| Earnings Yield | -6.29% |
| FCF Yield | -5.24% |
Analyst Forecast
The average price target for AMLX is $28.10, which is 30.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.10 |
| Price Target Difference | 30.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |